<p>根據 MarketBeat.com 報道，覆蓋 Biodesix, Inc.（NASDAQ:BDSX - 獲取免費報告）的六家研究公司對其股票給予了 “適度買入” 的平均評級。一位研究分析師給予該股票賣出建議，一位給予持有建議，四位給予買入建議。在過去一年中，覆蓋該股票的分析師的平均一年目標價為 32.50 美元。</p>
<p>幾家券商最近對 BDSX 發佈了報告。Weiss Ratings 在 12 月 22 日的研究報告中重新發布了對 Biodesix 股票的 “賣出（e+）” 評級。華爾街 Zen 在 11 月 8 日的報告中將 Biodesix 的評級從 “賣出” 上調至 “持有”。</p>
<p><strong>查看我們關於 Biodesix 的最新報告</strong></p>
<h2>Biodesix 價格表現</h2>
<p>Biodesix 股票在週二開盤價為 9.93 美元。Biodesix 的一年低點為 3.44 美元，一年高點為 20.40 美元。該公司的債務與股本比率為 41.11，速動比率為 1.84，流動比率為 1.84。該公司的 50 日移動平均價格為 8.25 美元，200 日移動平均價格為 7.94 美元。公司的市值為 7904 萬美元，市盈率為 -1.79，貝塔值為 0.66。</p>
<h2>Biodesix 的內部買賣</h2>
<p>在其他新聞中，董事 Jack W. Schuler 於 1 月 22 日以每股平均 10.96 美元的價格收購了 82,465 股 Biodesix 股票，總價值為 903,816.40 美元。購買後，該董事直接持有公司股票 1,463,210 股，價值約為 16,036,781.60 美元。這筆交易代表其持股比例增加了 5.97%。該收購在向證券交易委員會的備案中披露，相關文件可在此鏈接查看。在過去一個季度，內部人士購買了價值 2,084,616 美元的 182,465 股公司股票，並出售了價值 15,868 美元的 1,947 股。30.10% 的股票由公司內部人士持有。</p>
<h2>機構資金流入和流出</h2>
<p>對該公司的對沖基金最近進行了買賣。阿伯丁集團（Aberdeen Group plc）在第四季度購買了 Biodesix 的新股份，價值約為 1,784,000 美元。XTX Topco Ltd 在第二季度將其在 Biodesix 的持股增加了 99.4%。XTX Topco Ltd 現在擁有 205,647 股公司股票，價值 58,000 美元，此前在上個季度又收購了 102,494 股。Geode Capital Management LLC 在第四季度將其在 Biodesix 的持股增加了 5.6%。Geode Capital Management LLC 現在擁有 42,453 股公司股票，價值 289,000 美元，此前在此期間又購買了 2,235 股。Oracle Investment Management Inc. 在第三季度購買了 Biodesix 的新股份，價值 113,000 美元。最後，千禧管理公司（Millennium Management LLC）在第三季度收購了 Biodesix 的新股份，價值 113,000 美元。對沖基金和其他機構投資者持有公司 20.96% 的股票。</p>
<h2>Biodesix 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Biodesix, Inc 是一家總部位於科羅拉多州博爾德的商業階段分子診斷公司，開發和提供基於血液的測試，以改善肺部疾病（包括肺癌）的診斷和管理。該公司整合了先進的蛋白質組學和最近的基因組技術，提供旨在指導臨牀決策的非侵入性測試解決方案。Biodesix 運營着一家 CLIA 認證和 CAP 認可的實驗室，能夠大規模處理患者樣本並保持嚴格的質量標準。</p>
<p>該公司的旗艦產品 VeriStrat® 是一種蛋白質組學測試，將非小細胞肺癌患者分層為更可能從特定療法中受益的組別。</p>
<h2>進一步閲讀</h2>
<ul>
<li>我們更看好的五隻股票比 Biodesix 更好</li>
<li>沒有人談論的買入狂潮</li>
<li>如何每週收集 500-800 美元（黑石的系統）</li>
<li>特朗普的 AI 秘密：比英偉達快 100 倍</li>
<li>新法律：國會批准數字美元的設立？</li>
<li>他們剛剛試圖扼殺黃金</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkRTWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkRTWA"/></p>
<p><em>此即時新聞提醒由敍述科學技術和來自 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Biodesix 嗎？</h2>
<p>在考慮 Biodesix 之前，你會想聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前買入……而 Biodesix 並不在名單上。</p>
<p>雖然 Biodesix 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得買入。</p>
<p>在這裏查看這五隻股票</p>

動態生物技術與基因組 ETF - Invesco

基因免疫&健康關懷 ETF - iShares

生物科技 ETF - VanEck Vectors

標普生物技術 ETF - SPDR

納斯達克生物科技指數 ETF - iShares Nasdaq

BDSX

2 倍做多納斯達克生物技術 ETF - ProShares

基因改革 ETF - ARK

醫藥突破 ETF - ALPS

紐交所高增長板生物技術指數 ETF - First Trust

<p>Biodesix, Inc.（納斯達克代碼：BDSX）獲得了六家研究公司的 “適度買入” 平均評級。一位分析師將其評級為賣出，一位為持有，四位為買入。平均一年目標價為 32.50 美元。該股票開盤價為 9.93 美元，1 年最低價為 3.44 美元，最高價為 20.40 美元。內部人士 Jack W. Schuler 以每股 10.96 美元的價格購買了 82,465 股。對沖基金持有該股票的 20.96%。Biodesix 專注於肺部疾病的血液檢測，並運營一家 CLIA 認證的實驗室</p>

<p>Shares of Biodesix, Inc. (NASDAQ:BDSX - Get Free Report) have been given an average rating of &#34;Moderate Buy&#34; by the six research firms that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have given a buy recommendation to the company. The average 1 year price target among analysts that have covered the stock in the last year is $32.50.</p>
<div class="lb-trans"><p>根據 MarketBeat.com 報道，覆蓋 Biodesix, Inc.（NASDAQ:BDSX - 獲取免費報告）的六家研究公司對其股票給予了 “適度買入” 的平均評級。一位研究分析師給予該股票賣出建議，一位給予持有建議，四位給予買入建議。在過去一年中，覆蓋該股票的分析師的平均一年目標價為 32.50 美元。</p>
</div><p>Several brokerages have recently issued reports on BDSX. Weiss Ratings reissued a &#34;sell (e+)&#34; rating on shares of Biodesix in a research note on Monday, December 22nd. Wall Street Zen upgraded Biodesix from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a report on Saturday, November 8th.</p>
<div class="lb-trans"><p>幾家券商最近對 BDSX 發佈了報告。Weiss Ratings 在 12 月 22 日的研究報告中重新發布了對 Biodesix 股票的 “賣出（e+）” 評級。華爾街 Zen 在 11 月 8 日的報告中將 Biodesix 的評級從 “賣出” 上調至 “持有”。</p>
</div><p><strong>View Our Latest Report on Biodesix</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 Biodesix 的最新報告</strong></p>
</div><h2>Biodesix Price Performance</h2>
<div class="lb-trans"><h2>Biodesix 價格表現</h2>
</div><p>Biodesix stock opened at $9.93 on Tuesday. Biodesix has a 1 year low of $3.44 and a 1 year high of $20.40. The company has a debt-to-equity ratio of 41.11, a quick ratio of 1.84 and a current ratio of 1.84. The firm has a 50 day moving average price of $8.25 and a 200 day moving average price of $7.94. The company has a market cap of $79.04 million, a price-to-earnings ratio of -1.79 and a beta of 0.66.</p>
<div class="lb-trans"><p>Biodesix 股票在週二開盤價為 9.93 美元。Biodesix 的一年低點為 3.44 美元，一年高點為 20.40 美元。該公司的債務與股本比率為 41.11，速動比率為 1.84，流動比率為 1.84。該公司的 50 日移動平均價格為 8.25 美元，200 日移動平均價格為 7.94 美元。公司的市值為 7904 萬美元，市盈率為 -1.79，貝塔值為 0.66。</p>
</div><h2>Insider Buying and Selling at Biodesix</h2>
<div class="lb-trans"><h2>Biodesix 的內部買賣</h2>
</div><p>In other news, Director Jack W. Schuler acquired 82,465 shares of Biodesix stock in a transaction dated Thursday, January 22nd. The shares were acquired at an average cost of $10.96 per share, with a total value of $903,816.40. Following the purchase, the director directly owned 1,463,210 shares of the company's stock, valued at approximately $16,036,781.60. This trade represents a 5.97% increase in their position. The acquisition was disclosed in a filing with the Securities &amp; Exchange Commission, which is available at this link. Over the last quarter, insiders bought 182,465 shares of company stock valued at $2,084,616 and sold 1,947 shares valued at $15,868. 30.10% of the stock is owned by corporate insiders.</p>
<div class="lb-trans"><p>在其他新聞中，董事 Jack W. Schuler 於 1 月 22 日以每股平均 10.96 美元的價格收購了 82,465 股 Biodesix 股票，總價值為 903,816.40 美元。購買後，該董事直接持有公司股票 1,463,210 股，價值約為 16,036,781.60 美元。這筆交易代表其持股比例增加了 5.97%。該收購在向證券交易委員會的備案中披露，相關文件可在此鏈接查看。在過去一個季度，內部人士購買了價值 2,084,616 美元的 182,465 股公司股票，並出售了價值 15,868 美元的 1,947 股。30.10% 的股票由公司內部人士持有。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入和流出</h2>
</div><p>Hedge funds have recently bought and sold shares of the business. Aberdeen Group plc purchased a new stake in Biodesix during the fourth quarter worth approximately $1,784,000. XTX Topco Ltd lifted its holdings in shares of Biodesix by 99.4% during the 2nd quarter. XTX Topco Ltd now owns 205,647 shares of the company's stock valued at $58,000 after acquiring an additional 102,494 shares in the last quarter. Geode Capital Management LLC boosted its position in Biodesix by 5.6% during the 4th quarter. Geode Capital Management LLC now owns 42,453 shares of the company's stock worth $289,000 after purchasing an additional 2,235 shares during the period. Oracle Investment Management Inc. purchased a new stake in Biodesix during the 3rd quarter worth $113,000. Finally, Millennium Management LLC acquired a new stake in Biodesix in the 3rd quarter valued at $113,000. Hedge funds and other institutional investors own 20.96% of the company's stock.</p>
<div class="lb-trans"><p>對該公司的對沖基金最近進行了買賣。阿伯丁集團（Aberdeen Group plc）在第四季度購買了 Biodesix 的新股份，價值約為 1,784,000 美元。XTX Topco Ltd 在第二季度將其在 Biodesix 的持股增加了 99.4%。XTX Topco Ltd 現在擁有 205,647 股公司股票，價值 58,000 美元，此前在上個季度又收購了 102,494 股。Geode Capital Management LLC 在第四季度將其在 Biodesix 的持股增加了 5.6%。Geode Capital Management LLC 現在擁有 42,453 股公司股票，價值 289,000 美元，此前在此期間又購買了 2,235 股。Oracle Investment Management Inc. 在第三季度購買了 Biodesix 的新股份，價值 113,000 美元。最後，千禧管理公司（Millennium Management LLC）在第三季度收購了 Biodesix 的新股份，價值 113,000 美元。對沖基金和其他機構投資者持有公司 20.96% 的股票。</p>
</div><h2>Biodesix Company Profile</h2>
<div class="lb-trans"><h2>Biodesix 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Biodesix, Inc is a commercial-stage molecular diagnostics company headquartered in Boulder, Colorado, that develops and delivers blood-based tests to improve the diagnosis and management of lung diseases, including lung cancer. The company integrates advanced proteomic and, more recently, genomic technologies to offer noninvasive testing solutions designed to guide clinical decision-making. Biodesix operates a CLIA-certified and CAP-accredited laboratory, allowing it to process patient samples at scale and maintain rigorous quality standards.</p>
<div class="lb-trans"><p>Biodesix, Inc 是一家總部位於科羅拉多州博爾德的商業階段分子診斷公司，開發和提供基於血液的測試，以改善肺部疾病（包括肺癌）的診斷和管理。該公司整合了先進的蛋白質組學和最近的基因組技術，提供旨在指導臨牀決策的非侵入性測試解決方案。Biodesix 運營着一家 CLIA 認證和 CAP 認可的實驗室，能夠大規模處理患者樣本並保持嚴格的質量標準。</p>
</div><p>The company's flagship product, VeriStrat®, is a proteomic test that stratifies patients with non-small cell lung cancer into groups more likely to benefit from specific therapies.</p>
<div class="lb-trans"><p>該公司的旗艦產品 VeriStrat® 是一種蛋白質組學測試，將非小細胞肺癌患者分層為更可能從特定療法中受益的組別。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than Biodesix</li>
<li>The buying spree that no one is talking about</li>
<li>How to collect $500-$800 weekly (BlackRock's system)</li>
<li>Trump’s AI Secret: 100X Faster Than Nvidia</li>
<li>NEW LAW: Congress Approves Setup For Digital Dollar?</li>
<li>They just tried to kill gold</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 Biodesix 更好</li>
<li>沒有人談論的買入狂潮</li>
<li>如何每週收集 500-800 美元（黑石的系統）</li>
<li>特朗普的 AI 秘密：比英偉達快 100 倍</li>
<li>新法律：國會批准數字美元的設立？</li>
<li>他們剛剛試圖扼殺黃金</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkRTWA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=BDSX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和來自 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Biodesix Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Biodesix 嗎？</h2>
</div><p>Before you consider Biodesix, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Biodesix 之前，你會想聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Biodesix wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前買入……而 Biodesix 並不在名單上。</p>
</div><p>While Biodesix currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Biodesix 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得買入。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Biodesix, Inc. (NASDAQ:BDSX) Receives Average Rating of "Moderate Buy" from Brokerages

Market Beat

Biodesix

Biodesix, Inc. (NASDAQ:BDSX) 被券商給予 “適度買入” 的平均評級